+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients



Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients



Pediatric Transplantation 5(5): 359-364



While the overall incidence of post-transplant lymphoproliferative disease (PTLD) in pediatric liver transplant recipients has been reported to be 4-11%, the long-term risk of PTLD associated with primary tacrolimus therapy is unknown. Therefore, in order to determine the incidence and long-term risk of PTLD, the present study examined 131 pediatric recipients who underwent liver transplantation (LTx) between October 1989 and December 1991 and received primary tacrolimus therapy. This cohort of children was evaluated over an extended time-period (until December 31 1996) with a mean follow-up of 6.3 yr. Actuarial Kaplan-Meier analysis was utilized to determine the risk of PTLD over time. The overall incidence of PTLD was 13% (17/131) with an average age of 4.3 +/- 0.75 yr at diagnosis. Pretransplant Epstein-Barr virus (EBV) serologies were negative in 82%, positive in 12%, and not available in 6% of the patients. The median time to diagnosis of PTLD post-Tx was 11.9 months (mean 16.4 +/- 3.9, range 1.7-63.0 months). Mean tacrolimus dose and plasma trough level (as evaluated by enzyme-linked immunosorbent assay [ELISA]) at the time of diagnosis was 0.32 +/- 0.06 mg/kg/day and 1.3 +/- 0.3 ng/mL, respectively. The cumulative long-term risk of PTLD was found to increase over time: 3% at 6 months, 8% at 1 yr, 12% at 2 yr, 14% at 3 yr, and 15% at 4 and 5 yr. Mortality from PTLD was 12% (two of 17 patients). Primary tacrolimus use in pediatric LTx has a long-term risk of PTLD approaching 15%, with the majority of episodes (78%) occurring in the first 2 yr, suggesting that intense EBV surveillance should occur early post-transplantation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047075383

Download citation: RISBibTeXText

PMID: 11560756

DOI: 10.1034/j.1399-3046.2001.00021.x


Related references

Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 66(8): 1047-1052, 1998

An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 68(5): 650-655, 1999

Minimal toxicity and low incidence of post transplant lymphoproliferative disease with tacrolimus-based immunosupression in pediatric transplant recipients. JPGN 31(Suppl. 2): S267, 2000

Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Transplant Infectious Disease 20(1):, 2018

Incidence and risk factors of EBV related post transplant lymphoproliferative diseases in paediatric liver transplant recipients treated with tacrolimus. Hepatology 26(4 Part 2): 343A, 1997

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatric Transplantation 8(3): 243-248, 2004

Analysis of risk factors for post-transplant lymphoproliferative disease in pediatric lung transplant recipients with cystic fibrosis. Pediatric Research 43(4 Part 2): 131A, 1998

Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials. American Journal of Transplantation 19(5): 1545-1551, 2019

The use of objective case ascertainment to identify risk factors for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Hepatology 36(4 Part 2): 662A, 2002

Incidence of post-transplant lymphoproliferative disease among organ transplant recipients under tacrolimus immunosuppression. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35: 204, 1995

Long-term renal function in heart transplant recipients receiving tacrolimus (FK506) therapy. Journal of Heart and Lung Transplantation 20(2): 256, 2001

Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. Liver Transplantation and Surgery 4(2): 146-151, 1998

Plasmacytoma-like post-transplant lymphoproliferative disorder seen in pediatric combined liver and intestinal transplant recipients. Pediatric Blood and Cancer 60(11): E137-E139, 2013

Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Pediatric Hematology and Oncology 30(6): 520-531, 2013

Post transplant lymphoproliferative disease in pediatric lung transplant recipients. Journal of Heart & Lung Transplantation 17(1): 65, 1998